NASDAQ · CCCC
Healthcare · Biotechnology
$4.10
Down-$0.23 (-5.61%)
Updated Aug 28, 2026, 6:45 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
CCCC closed at $4.10 after 21 trading sessions, up 12.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $4.25 | $4.30 | $4.09 | $4.10 | 1.99M |
| Aug 26, 2026 | $4.17 | $4.24 | $4.03 | $4.24 | 1.86M |
| Aug 25, 2026 | $4.11 | $4.235 | $4.085 | $4.20 | 4.29M |
| Aug 24, 2026 | $3.97 | $4.14 | $3.81 | $4.10 | 1.75M |
| Aug 21, 2026 | $4.07 | $4.10 | $3.935 | $4.00 | 1.16M |
| Aug 20, 2026 | $4.14 | $4.15 | $3.832 | $4.03 | 2.27M |
| Aug 19, 2026 | $4.25 | $4.375 | $4.13 | $4.21 | 2.85M |
| Aug 18, 2026 | $4.21 | $4.30 | $4.105 | $4.18 | 2.88M |
| Aug 17, 2026 | $4.315 | $4.315 | $4.108 | $4.265 | 2.09M |
| Aug 14, 2026 | $4.07 | $4.315 | $3.895 | $4.24 | 3.4M |
| Aug 13, 2026 | $3.93 | $4.23 | $3.86 | $4.08 | 3.73M |
| Aug 12, 2026 | $3.95 | $3.995 | $3.8251 | $3.90 | 1.96M |
| Aug 11, 2026 | $3.84 | $4.00 | $3.64 | $3.87 | 3.09M |
| Aug 10, 2026 | $3.75 | $3.75 | $3.60 | $3.62 | 1.96M |
| Aug 7, 2026 | $3.69 | $3.7497 | $3.65 | $3.73 | 1.5M |
| Aug 6, 2026 | $3.62 | $3.72 | $3.58 | $3.64 | 1.82M |
| Aug 5, 2026 | $3.61 | $3.68 | $3.54 | $3.62 | 2.56M |
| Aug 4, 2026 | $3.57 | $3.6385 | $3.47 | $3.61 | 2.52M |
| Aug 3, 2026 | $3.50 | $3.535 | $3.36 | $3.50 | 2.24M |
| Jul 31, 2026 | $3.66 | $3.66 | $3.45 | $3.48 | 1.95M |
| Jul 30, 2026 | $3.53 | $3.69 | $3.515 | $3.66 | 3.15M |
The latest Smart Investors Daily articles mentioning CCCC.
CCCC research
Company profile and research snapshot.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 1, 2026 | Evercore ISI Group | Outperform | — |
| Feb 27, 2026 | Barclays | Overweight | — |
| Feb 23, 2026 | Brookline Capital | Buy | — |
| Dec 17, 2025 | Barclays | Overweight | — |
| Dec 2, 2025 | TD Cowen | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 11, 2026
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +21.74% and +10.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Aug 11, 2026
Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 Phase 1 Data Presented at European Hematology Association (EHA) 2026 Congress Further Support Cemsidomide’s Potential Best-in-Class Profile in Multiple Myeloma Phase 1b Trial of Cemsidomide in Combination With Approved Standard of Care Multiple Myeloma Therapies On Track to Initiate in 1H 2027 WATERTOWN, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) --
Benzinga · Aug 11, 2026
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 51.35 percent increase over losses of $(0.37) per share from
Yahoo · Aug 10, 2026
WATERTOWN, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 162,880 shares of the Company’s common stock to one new employee (the “Inducement Grant”
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CCCC.
